OmegaQuant Analytics, the producer of The Omega-3 Index, has launched a new Prenatal DHA Test developed for expecting mothers to monitor their omega-3 DHA level.
Photo © iStockphoto.com/Rinelle
OmegaQuant Analytics (Siox Falls, SD), the producer of The Omega-3 Index, has launched a new Prenatal DHA Test developed for expecting mothers to monitor their omega-3 DHA level. This is an important measure for pregnant women because there is evidence that deficiency in omega-3 long chain polyunsaturated fatty acids can increase the risk of preterm birth.
A meta-analysis1 conducted by Cochrane of 70 randomized control trials, involving 19,927 women, found that preterm birth (<37 weeks of gestation) and very preterm birth (<34 weeks of gestation) was reduced by 11% and 42% respectively when women took omega-3 supplements, and determined that it is an effective strategy for reducing the risk of preterm births. Another recent study2 found that the risk of early preterm birth (<34 weeks of gestation) was 10 times higher in women in the lowest quintile, with an EPA and DHA omega-3 concentration of less than 1.6% of total plasma fatty acids.
Using this data, and converting the EPA and DHA plasma levels to red blood cell DHA levels, OmegaQuant determined that pregnant women should strive to have DHA levels of at least 5% (meaning that 5% of her red blood cell fatty acids are DHA). “In a study3 we published in December, we estimated that 70% of women of childbearing age in the US are below the 5% DHA cutoff. There are no known risks to having a DHA level that is too high in pregnancy, except for the potential of carrying a baby past 40 weeks. Still, the longer a baby can stay in the womb, the lower the chances are for complications,” said Kristina Harris Jackson, PhD, RD, a research associate at OmegaQuant Analytics, in a press release. “It’s hard to think of a more important biomarker than prenatal DHA levels that can be safely and easily modified and has such potentially consequential outcomes.”
1. Middleton P. et al. “Omega-3 fatty acid addition during pregnancy.” Cochrane Database of Systematic Reviews, vol 11 (November 2018)
2. Olsen S.F. et al. “Plasma concentrations of long chain omega-3 fatty acids in early and mid-pregnancy and risk of early preterm birth.” EBioMedicine, vol 35 (September 2018): 325-333
3. Jackson K.H et al. “A prenatal DHA test to help identify women at increased risk for early preterm birth: a proposal.” Nutrients, vol 10, no. 12 (December 2018)
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.
OmniActive partners with CRN to raise awareness about macular carotenoids for prenatal health
May 6th 2024OmniActive Health Technologies has announced a partnership with the Council for Responsible Nutrition to educate and raise awareness about the role of lutein and zeaxanthin in supporting maternal and fetal health during pregnancy among obstetricians, gynecologists, and other maternal healthcare practitioners.